-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, the Journal of Clinical Oncology published the long-term survival outcomes of the Phase II clinical study CALGB 40603 (NCT00861705)
Recently, the Journal of Clinical Oncology published the long-term survival outcomes of the Phase II clinical study CALGB 40603 (NCT00861705)
Long-term outcomes (LTOs) of 443 treated patients were assessed using the Kaplan-Meier method
Long-term outcomes (LTOs) of 443 treated patients were assessed using the Kaplan-Meier method
Of the 443 mITT population, 426 underwent surgery
Of the 443 mITT population, 426 underwent surgery
In patients who achieved pCR (205/443, 46.
In patients who achieved pCR (205/443, 46.
The addition of bevacizumab (HR, 0.
In conclusion, the CALGB 40603 study showed that the addition of carboplatin and bevacizumab did not improve LTOs in patients despite higher pCR rates
In conclusion, the CALGB 40603 study showed that the addition of carboplatin and bevacizumab did not improve LTOs in patients despite higher pCR rates
Original source:
Original source:Shepherd JH, Ballman K, Polley MC, Campbell JD, Fan C, Selitsky S, Fernandez-Martinez A, Parker JS, Hoadley KA, Hu Z, Li Y, Soloway MG, Spears PA, Singh B, Tolaney SM, Somlo G, Port ER, Ma C, Kuzma C, Mamounas E, Golshan M, Bellon JR, Collyar D, Hahn OM, Hudis CA, Winer EP, Partridge A, Hyslop T, Carey LA, Perou CM, Sikov WM.
Shepherd JH, Ballman K, Polley MC, Campbell JD, Fan C, Selitsky S, Fernandez-Martinez A, Parker JS, Hoadley KA, Hu Z, Li Y, Soloway MG, Spears PA, Singh B, Tolaney SM, Somlo G, Port ER, Ma C, Kuzma C, Mamounas E, Golshan M, Bellon JR, Collyar D, Hahn OM, Hudis CA, Winer EP, Partridge A, Hyslop T, Carey LA, Perou CM, Sikov WM.
CALGB 40603 (Alliance) : Long-Term Outcomes and Genomic Correlates of Response and Survival After Neoadjuvant Chemotherapy With or Without Carboplatin and Bevacizumab in Triple-Negative Breast Cancer.
J Clin Oncol.
2022 Jan 19:JCO2101506.
doi: 10.
1200/JCO.
21.
01506.
Epub ahead of print .
PMID: 35044810.
Leave a message here
